Raymond Hakim
Last active: 6/9/2014

Profile

Dr. Raymond Hakim is currently a clinical Professor of Medicine in the Division of Nephrology.  He brings a tremendous amount of experience to the team at Vanderbilt.

Dr. Hakim was the Chief Medical Officer and Senior Executive Vice President, Clinical and Scientific Affairs for Fresenius Medical Services until December 2011.   He started his career as an engineer graduating from MIT and worked as a research engineer until he was accepted into medical school.  He has been a faculty member of Harvard and Brigham  and Women’s Hospital in Boston before joining the faculty at Vanderbilt in 1987 which he was the Clinical Division Director of Nephrology as well as Medical Director of Vanderbilt Dialysis. He has done internationally recognized research in the areas of dialysis and the care of dialysis patients.

In 1995, Dr. Hakim became one of the founders of Renal Care group which in 2005 had the lowest mortality and morbidity rate among other dialysis providers as published by the USRDS.    He attributes this success to a team effort in applying the principles of Continuous Quality Improvement throughout the organization. 

Through Dr. Hakim’s 190 publications as well as many past and current presentations, he educates many faculty nationally regarding the treatment of kidney disease.

More information can be found on Vanderbilt School of Medicine's website.

Click here to view:  Division of Nephrology and Hypertension

 

 

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. First-year outcomes of incident peritoneal dialysis patients in the United States. Pulliam J, Li NC, Maddux F, Hakim R, Finkelstein FO, Lacson E (2014) Am J Kidney Dis 64(5): 761-9
    › Primary publication · 24927898 (PubMed)
  2. Reducing avoidable rehospitalization in ESRD: a shared accountability. Hakim RM, Collins AJ (2014) J Am Soc Nephrol 25(9): 1891-3
    › Primary publication · 24812162 (PubMed) · PMC4147993 (PubMed Central)
  3. Reducing re-hospitalizations for dialysis patients. Hakim R, Weiner D, Wingard R (2014) Nephrol News Issues 28(3): 34, 36
    › Primary publication · 24720014 (PubMed)
  4. Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. Derebail VK, Lacson EK, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM (2014) J Am Soc Nephrol 25(4): 819-26
    › Primary publication · 24459231 (PubMed) · PMC3968502 (PubMed Central)
  5. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S, Kaplan M, Chonchol M, Hakim RM (2014) J Am Soc Nephrol 25(3): 623-33
    › Primary publication · 24371300 (PubMed) · PMC3935590 (PubMed Central)
  6. Dialysis frequency versus dialysis time, that is the question. Hakim RM, Saha S (2014) Kidney Int 85(5): 1024-9
    › Primary publication · 24336033 (PubMed)
  7. Improving outcomes by changing hemodialysis practice patterns. Fissell R, Hakim RM (2013) Curr Opin Nephrol Hypertens 22(6): 675-80
    › Primary publication · 24100220 (PubMed)
  8. Worldwide, mortality risk is high soon after initiation of hemodialysis. Robinson BM, Zhang J, Morgenstern H, Bradbury BD, Ng LJ, McCullough KP, Gillespie BW, Hakim R, Rayner H, Fort J, Akizawa T, Tentori F, Pisoni RL (2014) Kidney Int 85(1): 158-65
    › Primary publication · 23802192 (PubMed) · PMC3877739 (PubMed Central)
  9. A quality initiative. Reducing rates of hospitalizations by objectively monitoring volume removal. Parker TF, Hakim R, Nissenson AR, Krishnan M, Bond TC, Chan K, Maddux FW, Glassock R (2013) Nephrol News Issues 27(3): 30-2, 34-6
    › Primary publication · 23581174 (PubMed)
  10. In reply to 'A more cautious stance on nutritional supplementation for hypoalbuminemia is justified' and 'Intradialytic oral nutritional supplements improve quality of life'. Lacson E, Maddux FW, Hakim RM (2013) Am J Kidney Dis 61(2): 350
    › Primary publication · 23318015 (PubMed)
  11. Hemodialysis access usage patterns in the incident dialysis year and associated catheter-related complications. Xue H, Ix JH, Wang W, Brunelli SM, Lazarus M, Hakim R, Lacson E (2013) Am J Kidney Dis 61(1): 123-30
    › Primary publication · 23159234 (PubMed) · PMC3532948 (PubMed Central)
  12. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. Chan KE, Warren HS, Thadhani RI, Steele DJ, Hymes JL, Maddux FW, Hakim RM (2012) J Am Soc Nephrol 23(9): 1551-9
    › Primary publication · 22904350 (PubMed) · PMC3431413 (PubMed Central)
  13. Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report. Lacson E, Wang W, Zebrowski B, Wingard R, Hakim RM (2012) Am J Kidney Dis 60(4): 591-600
    › Primary publication · 22632807 (PubMed)
  14. Dialysis at a crossroads--Part II: A call for action. Parker TF, Straube BM, Nissenson A, Hakim RM, Steinman TI, Glassock RJ (2012) Clin J Am Soc Nephrol 7(6): 1026-32
    › Primary publication · 22498499 (PubMed)
  15. RightReturn. Partnering to reduce the high rate of hospital readmission for dialysis-dependent patients. Wingard RL, Chan KE, Hakim R (2012) Nephrol News Issues 26(3): 20-2
    › Primary publication · 22479972 (PubMed)
  16. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. Lacson E, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Ofsthun N, Lazarus M, Hakim RM (2012) J Am Soc Nephrol 23(4): 687-95
    › Primary publication · 22362905 (PubMed) · PMC3312497 (PubMed Central)
  17. Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients. Lacson E, Li NC, Guerra-Dean S, Lazarus M, Hakim R, Finkelstein FO (2012) Nephrol Dial Transplant 27(7): 2921-8
    › Primary publication · 22273670 (PubMed)
  18. Access survival amongst hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty. Chan KE, Pflederer TA, Steele DJ, Lilly MP, Ikizler TA, Maddux FW, Hakim RM (2011) Clin J Am Soc Nephrol 6(11): 2669-80
    › Primary publication · 21959600 (PubMed) · PMC3359572 (PubMed Central)
  19. Early outcomes among those initiating chronic dialysis in the United States. Chan KE, Maddux FW, Tolkoff-Rubin N, Karumanchi SA, Thadhani R, Hakim RM (2011) Clin J Am Soc Nephrol 6(11): 2642-9
    › Primary publication · 21959599 (PubMed) · PMC3359565 (PubMed Central)
  20. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ (2011) Kidney Int 80(9): 978-985
    › Primary publication · 21775975 (PubMed) · PMC3656595 (PubMed Central)
  21. Effects of a nationwide predialysis educational program on modality choice, vascular access, and patient outcomes. Lacson E, Wang W, DeVries C, Leste K, Hakim RM, Lazarus M, Pulliam J (2011) Am J Kidney Dis 58(2): 235-42
    › Primary publication · 21664016 (PubMed)
  22. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization. Lacson E, Hakim RM (2011) Am J Kidney Dis 57(4): 547-9
    › Primary publication · 21333423 (PubMed)
  23. International Quotidian Dialysis Registry: Annual report 2010. Lindsay RM, Suri RS, Moist LM, Garg AX, Cuerden M, Langford S, Hakim R, Ofsthun NJ, McDonald SP, Hawley C, Caskey FJ, Couchoud C, Awaraji C, Nesrallah GE (2011) Hemodial Int 15(1): 15-22
    › Primary publication · 21231997 (PubMed)
  24. Dialysis at a crossroads: 50 years later. Parker T, Hakim R, Nissenson AR, Steinman T, Glassock RJ (2011) Clin J Am Soc Nephrol 6(2): 457-61
    › Primary publication · 21148247 (PubMed)
  25. Abandoning peracetic acid-based dialyzer reuse is associated with improved survival. Lacson E, Wang W, Mooney A, Ofsthun N, Lazarus JM, Hakim RM (2011) Clin J Am Soc Nephrol 6(2): 297-302
    › Primary publication · 20947788 (PubMed) · PMC3052219 (PubMed Central)
  26. Change in vascular access and hospitalization risk in long-term hemodialysis patients. Lacson E, Wang W, Lazarus JM, Hakim RM (2010) Clin J Am Soc Nephrol 5(11): 1996-2003
    › Primary publication · 20884778 (PubMed) · PMC3001775 (PubMed Central)
  27. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Williams ME, Lacson E, Wang W, Lazarus JM, Hakim R (2010) Clin J Am Soc Nephrol 5(9): 1595-601
    › Primary publication · 20671217 (PubMed) · PMC2974399 (PubMed Central)
  28. Low health literacy associates with increased mortality in ESRD. Cavanaugh KL, Wingard RL, Hakim RM, Eden S, Shintani A, Wallston KA, Huizinga MM, Elasy TA, Rothman RL, Ikizler TA (2010) J Am Soc Nephrol 21(11): 1979-85
    › Primary publication · 20671215 (PubMed) · PMC3014012 (PubMed Central)
  29. Digoxin associates with mortality in ESRD. Chan KE, Lazarus JM, Hakim RM (2010) J Am Soc Nephrol 21(9): 1550-9
    › Primary publication · 20576808 (PubMed) · PMC3013530 (PubMed Central)
  30. Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Chan KE, Thadhani R, Lazarus JM, Hakim RM (2010) Clin J Am Soc Nephrol 5(5): 856-66
    › Primary publication · 20338963 (PubMed) · PMC2863967 (PubMed Central)
  31. A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients. Lacson E, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim RM (2010) Clin J Am Soc Nephrol 5(2): 252-60
    › Primary publication · 20019120 (PubMed) · PMC2827595 (PubMed Central)
  32. The "right" of passage: surviving the first year of dialysis. Wingard RL, Chan KE, Lazarus JM, Hakim RM (2009) Clin J Am Soc Nephrol : S114-20
    › Primary publication · 19995993 (PubMed)
  33. Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program. Lacson E, Wang W, Lester K, Ofsthun N, Lazarus JM, Hakim RM (2010) Clin J Am Soc Nephrol 5(2): 220-6
    › Primary publication · 19965529 (PubMed) · PMC2827598 (PubMed Central)
  34. Association between achievement of hemodialysis quality-of-care indicators and quality-of-life scores. Lacson E, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim R (2009) Am J Kidney Dis 54(6): 1098-107
    › Primary publication · 19782455 (PubMed)
  35. Change in vascular access and mortality in maintenance hemodialysis patients. Lacson E, Wang W, Lazarus JM, Hakim RM (2009) Am J Kidney Dis 54(5): 912-21
    › Primary publication · 19748717 (PubMed)
  36. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) J Am Soc Nephrol 20(10): 2223-33
    › Primary publication · 19713308 (PubMed) · PMC2754104 (PubMed Central)
  37. Hemodialysis access failure: a call to action--revisited. Hakim RM, Himmelfarb J (2009) Kidney Int 76(10): 1040-8
    › Primary publication · 19710629 (PubMed)
  38. International Quotidian Dialysis Registry: annual report 2009. Nesrallah GE, Suri RS, Moist LM, Cuerden M, Groeneweg KE, Hakim R, Ofsthun NJ, McDonald SP, Hawley C, Caskey FJ, Couchoud C, Awaraji C, Lindsay RM (2009) Hemodial Int 13(3): 240-9
    › Primary publication · 19703054 (PubMed)
  39. Anabolic interventions in ESRD: light at the end of the tunnel? Hakim RM, Ikizler TA (2009) Am J Kidney Dis 54(2): 201-4
    › Primary publication · 19556045 (PubMed)
  40. Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. Chan KE, Lazarus JM, Wingard RL, Hakim RM (2009) Kidney Int 76(3): 331-41
    › Primary publication · 19516243 (PubMed)
  41. Oral protein supplementation alone improves anabolism in a dose-dependent manner in chronic hemodialysis patients. Sundell MB, Cavanaugh KL, Wu P, Shintani A, Hakim RM, Ikizler TA (2009) J Ren Nutr 19(5): 412-21
    › Primary publication · 19500999 (PubMed) · PMC2758490 (PubMed Central)
  42. Why is the mortality of dialysis patients in the United States much higher than the rest of the world? Foley RN, Hakim RM (2009) J Am Soc Nephrol 20(7): 1432-5
    › Primary publication · 19443632 (PubMed)
  43. Hemodialysis facility-based quality-of-care indicators and facility-specific patient outcomes. Lacson E, Wang W, Lazarus JM, Hakim RM (2009) Am J Kidney Dis 54(3): 490-7
    › Primary publication · 19406544 (PubMed)
  44. Patient dialysis knowledge is associated with permanent arteriovenous access use in chronic hemodialysis. Cavanaugh KL, Wingard RL, Hakim RM, Elasy TA, Ikizler TA (2009) Clin J Am Soc Nephrol 4(5): 950-6
    › Primary publication · 19389825 (PubMed) · PMC2676183 (PubMed Central)
  45. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) J Am Soc Nephrol 20(4): 872-81
    › Primary publication · 19297555 (PubMed) · PMC2663838 (PubMed Central)
  46. Reducing early mortality in hemodialysis patients. Hakim RM (2008) Curr Opin Nephrol Hypertens 17(6): 595-9
    › Primary publication · 18941352 (PubMed)
  47. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Lacson E, Wang W, Hakim RM, Teng M, Lazarus JM (2009) Am J Kidney Dis 53(1): 79-90
    › Primary publication · 18930570 (PubMed)
  48. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH (2009) Nephrol Dial Transplant 24(3): 919-25
    › Primary publication · 18840893 (PubMed)
  49. The association of race with erythropoietin dose in patients on long-term hemodialysis. Lacson E, Rogus J, Teng M, Lazarus JM, Hakim RM (2008) Am J Kidney Dis 52(6): 1104-14
    › Primary publication · 18824287 (PubMed)
  50. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Williams ME, Lacson E, Teng M, Hakim RM, Lazarus JM (2009) Am J Nephrol 29(1): 54-61
    › Primary publication · 18689979 (PubMed)
  51. The International Quotidian Dialysis Registry: Annual report 2008. Nesrallah GE, Suri RS, Moist LM, Ofsthun NJ, Hakim R, McDonald SP, Marshall MR, Carter ST, Lindsay RM, International Quotidian Dialysis Registry (2008) Hemodial Int 12(3): 281-9
    › Primary publication · 18638080 (PubMed)
  52. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hung A, Pupim L, Yu C, Shintani A, Siew E, Ayus C, Hakim RM, Ikizler TA (2008) Hemodial Int 12(2): 236-43
    › Primary publication · 18394058 (PubMed)
  53. The role of the medical director: changing with the times. Maddux FW, Maddux DW, Hakim RM (2008) Semin Dial 21(1): 54-7
    › Primary publication · 18251959 (PubMed)
  54. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. Lacson E, Ikizler TA, Lazarus JM, Teng M, Hakim RM (2007) J Ren Nutr 17(6): 363-71
    › Primary publication · 17971308 (PubMed)
  55. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Wingard RL, Pupim LB, Krishnan M, Shintani A, Ikizler TA, Hakim RM (2007) Clin J Am Soc Nephrol 2(6): 1170-5
    › Primary publication · 17942761 (PubMed)
  56. Balancing Fistula First with Catheters Last. Lacson E, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM (2007) Am J Kidney Dis 50(3): 379-95
    › Primary publication · 17720517 (PubMed)
  57. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective. Lazarus JM, Hakim RM (2007) Am J Kidney Dis 50(3): 366-70
    › Primary publication · 17720515 (PubMed)
  58. Translating epoetin research into practice: the role of government and the use of scientific evidence. Lazarus JM, Hakim RM (2006) Nephrol News Issues 20(13): 12, 22
    › Primary publication · 17168053 (PubMed)
  59. Peritoneal dialysis in large dialysis chains. Pulliam J, Hakim R, Lazarus M (2006) Perit Dial Int 26(4): 435-7
    › Primary publication · 16881337 (PubMed)
  60. The emperor has no clothes (but has a catheter): a perspective on the state of chronic kidney disease care. Lazarus JM, Hakim RM, Maddux FW, Amedia CA (2005) Nephrol News Issues 19(12): 45-6, 48
    › Primary publication · 16315544 (PubMed)
  61. Uremic malnutrition is a predictor of death independent of inflammatory status. Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA (2004) Kidney Int 66(5): 2054-60
    › Primary publication · 15496179 (PubMed)
  62. Urea space and total body water measurements by stable isotopes in patients with acute renal failure. Ikizler TA, Sezer MT, Flakoll PJ, Hariachar S, Kanagasundaram NS, Gritter N, Knights S, Shyr Y, Paganini E, Hakim RM, Himmelfarb J, PICARD Study Group (2004) Kidney Int 65(2): 725-32
    › Primary publication · 14717948 (PubMed)
  63. The extent of uremic malnutrition at the time of initiation of maintenance hemodialysis is associated with subsequent hospitalization. Pupim LB, Evanson JA, Hakim RM, Ikizler TA (2003) J Ren Nutr 13(4): 259-66
    › Primary publication · 14566762 (PubMed)
  64. Oxidative stress in uremia. Himmelfarb J, Hakim RM (2003) Curr Opin Nephrol Hypertens 12(6): 593-8
    › Primary publication · 14564195 (PubMed)
  65. Quality of care in profit vs not-for-profit dialysis centers. Bosch J, Hakim RM, Lazarus JM, McAllister CJ (2003) JAMA 289(23): 3087-8; author reply 3089-90
    › Primary publication · 12813111 (PubMed)
  66. Increased resting energy expenditure in patients with end-stage renal disease. Neyra R, Chen KY, Sun M, Shyr Y, Hakim RM, Ikizler TA (2003) JPEN J Parenter Enteral Nutr 27(1): 36-42
    › Primary publication · 12549596 (PubMed)
  67. Approaches to the reversal of malnutrition, inflammation, and atherosclerosis in end-stage renal disease. Caglar K, Hakim RM, Ikizler TA (2002) Nutr Rev 60(11): 378-87
    › Primary publication · 12462522 (PubMed)
  68. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) Kidney Int 62(5): 1524-38
    › Primary publication · 12371953 (PubMed)
  69. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J (2002) Clin Nephrol 58(3): 190-7
    › Primary publication · 12356187 (PubMed)
  70. Inflammatory signals associated with hemodialysis. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA (2002) Kidney Int 62(4): 1408-16
    › Primary publication · 12234313 (PubMed)
  71. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA (2002) J Clin Invest 110(4): 483-92
    › Primary publication · 12189242 (PubMed) · PMC150418 (PubMed Central)
  72. Therapeutic effects of oral nutritional supplementation during hemodialysis. Caglar K, Fedje L, Dimmitt R, Hakim RM, Shyr Y, Ikizler TA (2002) Kidney Int 62(3): 1054-9
    › Primary publication · 12164890 (PubMed)
  73. Improvement in nutritional parameters after initiation of chronic hemodialysis. Pupim LB, Kent P, Caglar K, Shyr Y, Hakim RM, Ikizler TA (2002) Am J Kidney Dis 40(1): 143-51
    › Primary publication · 12087572 (PubMed)
  74. The for-profit providers. Bander SJ, Hakim R, Lazarus MJ, Lindenfeld S (2000) Nephrol News Issues 14(3): 13-5
    › Primary publication · 11933347 (PubMed)
  75. Urea volume of distribution exceeds total body water in patients with acute renal failure. Himmelfarb J, Evanson J, Hakim RM, Freedman S, Shyr Y, Ikizler TA (2002) Kidney Int 61(1): 317-23
    › Primary publication · 11786114 (PubMed)
  76. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Ikizler TA, Pupim LB, Brouillette JR, Levenhagen DK, Farmer K, Hakim RM, Flakoll PJ (2002) Am J Physiol Endocrinol Metab 282(1): E107-16
    › Primary publication · 11739090 (PubMed)
  77. Recombinant human growth hormone in patients with acute renal failure. Saadeh E, Ikizler TA, Shyr Y, Hakim RM, Himmelfarb J (2001) J Ren Nutr 11(4): 212-9
    › Primary publication · 11680002 (PubMed)
  78. Vascular access blood flow monitoring reduces access morbidity and costs. McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA (2001) Kidney Int 60(3): 1164-72
    › Primary publication · 11532113 (PubMed)
  79. Use of vascular access blood flow to evaluate vascular access. Hakim RM, Ikizler TA (2001) Am J Kidney Dis 37(2): 451-2
    › Primary publication · 11157393 (PubMed)
  80. The current and future state of the ESRD program: a provider roundtable. Nissenson AR, Lazarus JM, Lindenfeld SM, Hakim RM, Bander SJ (2000) Semin Nephrol 20(6): 543-55
    › Primary publication · 11111856 (PubMed)
  81. Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. Neyra NR, Hakim RM, Shyr Y, Ikizler TA (2000) J Ren Nutr 10(4): 184-90
    › Primary publication · 11070145 (PubMed)
  82. Clinical implications of biocompatibility in blood purification membranes. Hakim RM (2000) Nephrol Dial Transplant : 16-20
    › Primary publication · 11051033 (PubMed)
  83. An evolving partnership: the role of the Centers for Disease Control in the dialysis community. Wingard RL, Hakim RM (2000) Semin Dial 13(2): 71-4
    › Primary publication · 10795108 (PubMed)
  84. The potential of intradialytic parenteral nutrition: A review. Pupim LB, Kent P, Hakim R (1999) Miner Electrolyte Metab 25(4-6): 317-23
    › Primary publication · 10681659 (PubMed)
  85. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Matsuo K, Ikizler TA, Hoover RL, Nakamoto M, Yasunaga C, Pupim LB, Hakim RM (2000) Kidney Int 57(2): 697-708
    › Primary publication · 10652049 (PubMed)
  86. Risk factors for hospitalization in well-dialyzed chronic hemodialysis patients. Becker BN, Coomer RW, Fotiadis C, Evanson J, Shyr Y, Hakim RM (1999) Am J Nephrol 19(5): 565-70
    › Primary publication · 10575185 (PubMed)
  87. Intradialytic serial vascular access flow measurements. Rehman SU, Pupim LB, Shyr Y, Hakim R, Ikizler TA (1999) Am J Kidney Dis 34(3): 471-7
    › Primary publication · 10469857 (PubMed)
  88. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM (1999) Kidney Int 55(5): 1945-51
    › Primary publication · 10231458 (PubMed)
  89. Obesity and mortality in ESRD: is it good to be fat? Hakim RM, Lowrie E (1999) Kidney Int 55(4): 1580-1
    › Primary publication · 10201027 (PubMed)
  90. Measurement of the delivery of dialysis in acute renal failure. Evanson JA, Ikizler TA, Wingard R, Knights S, Shyr Y, Schulman G, Himmelfarb J, Hakim RM (1999) Kidney Int 55(4): 1501-8
    › Primary publication · 10201016 (PubMed)
  91. Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure. Himmelfarb J, McMonagle E, Holbrook D, Hakim R (1999) Kidney Int 55(2): 659-66
    › Primary publication · 9987090 (PubMed)
  92. Proposed clinical trials in the evaluation of intradialytic parenteral nutrition. Hakim RM (1999) Am J Kidney Dis 33(1): 217-20
    › Primary publication · 9915296 (PubMed)
  93. Relationship of dialysis membrane and cause-specific mortality. Bloembergen WE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, Port FK (1999) Am J Kidney Dis 33(1): 1-10
    › Primary publication · 9915261 (PubMed)
  94. Influence of the dialysis membrane on outcome of ESRD patients. Hakim RM (1998) Am J Kidney Dis 32(6 Suppl 4): S71-5
    › Primary publication · 9892369 (PubMed)
  95. Change in access blood flow over time predicts vascular access thrombosis. Neyra NR, Ikizler TA, May RE, Himmelfarb J, Schulman G, Shyr Y, Hakim RM (1998) Kidney Int 54(5): 1714-9
    › Primary publication · 9844149 (PubMed)
  96. Prescribed versus delivered dialysis in acute renal failure patients. Evanson JA, Himmelfarb J, Wingard R, Knights S, Shyr Y, Schulman G, Ikizler TA, Hakim RM (1998) Am J Kidney Dis 32(5): 731-8
    › Primary publication · 9820441 (PubMed)
  97. Hemodialysis access failure: a call to action. Hakim R, Himmelfarb J (1998) Kidney Int 54(4): 1029-40
    › Primary publication · 9767519 (PubMed)
  98. Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study. Parker RA, Himmelfarb J, Tolkoff-Rubin N, Chandran P, Wingard RL, Hakim RM (1998) Am J Kidney Dis 32(3): 432-43
    › Primary publication · 9740160 (PubMed)
  99. Influence of high-flux biocompatible membrane on carpal tunnel syndrome and mortality. Hakim RM (1998) Am J Kidney Dis 32(2): 338-40; discussion 340-3
    › Primary publication · 9708624 (PubMed)
  100. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. Himmelfarb J, Tolkoff Rubin N, Chandran P, Parker RA, Wingard RL, Hakim R (1998) J Am Soc Nephrol 9(2): 257-66
    › Primary publication · 9527402 (PubMed)
  101. The medical and economical advantages of early referral of chronic renal failure patients to renal specialists. Ismail N, Neyra R, Hakim R (1998) Nephrol Dial Transplant 13(2): 246-50
    › Primary publication · 9509429 (PubMed)
  102. Predictive measures of vascular access thrombosis: a prospective study. May RE, Himmelfarb J, Yenicesu M, Knights S, Ikizler TA, Schulman G, Hernanz-Schulman M, Shyr Y, Hakim RM (1997) Kidney Int 52(6): 1656-62
    › Primary publication · 9407514 (PubMed)
  103. The relationship between quality of care and financial performance in dialysis: "doing well by doing good". Thornton TA, Hakim RM (1997) Adv Ren Replace Ther 4(4): 350-8
    › Primary publication · 9356687 (PubMed)
  104. End-stage renal disease. Parker T, Hakim R, Ismail N (1997) Semin Nephrol 17(4): 253-6
    › Primary publication · 9241711 (PubMed)
  105. Dialysis membrane biocompatibility and mortality and morbidity in acute renal failure. Himmelfarb J, Hakim RM (1997) J Nephrol 10(2): 63-4
    › Primary publication · 9238611 (PubMed)
  106. Meaningful rehabilitation of the end-stage renal disease patient. Thornton TA, Hakim RM (1997) Semin Nephrol 17(3): 246-52
    › Primary publication · 9165654 (PubMed)
  107. The use of biocompatible dialysis membranes in acute renal failure. Himmelfarb J, Hakim RM (1997) Adv Ren Replace Ther 4(2 Suppl 1): 72-80
    › Primary publication · 9113243 (PubMed)
  108. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. Becker BN, Himmelfarb J, Henrich WL, Hakim RM (1997) J Am Soc Nephrol 8(3): 475-86
    › Primary publication · 9071717 (PubMed)
  109. Increased energy expenditure in hemodialysis patients. Ikizler TA, Wingard RL, Sun M, Harvell J, Parker RA, Hakim RM (1996) J Am Soc Nephrol 7(12): 2646-53
    › Primary publication · 8989743 (PubMed)
  110. Nitrogen balance in hospitalized chronic hemodialysis patients. Ikizler TA, Greene JH, Yenicesu M, Schulman G, Wingard RL, Hakim RM (1996) Kidney Int Suppl : S53-6
    › Primary publication · 8941922 (PubMed)
  111. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L (1996) Kidney Int 50(2): 566-70
    › Primary publication · 8840287 (PubMed)
  112. The dose of hemodialysis and patient mortality. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM (1996) Kidney Int 50(2): 550-6
    › Primary publication · 8840285 (PubMed)
  113. Nutrition in end-stage renal disease. Ikizler TA, Hakim RM (1996) Kidney Int 50(2): 343-57
    › Primary publication · 8840260 (PubMed)
  114. Recent advances in the biocompatibility of haemodialysis membranes. Hakim RM (1995) Nephrol Dial Transplant : 7-11
    › Primary publication · 8825426 (PubMed)
  115. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Parker TF, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM (1996) Kidney Int 49(2): 551-6
    › Primary publication · 8821843 (PubMed)
  116. Effects of recombinant human growth hormone on plasma and dialysate amino acid profiles in CAPD patients. Ikizler TA, Wingard RL, Flakoll PJ, Schulman G, Parker RA, Hakim RM (1996) Kidney Int 50(1): 229-34
    › Primary publication · 8807592 (PubMed)
  117. Water treatment for hemodialysis. Ismail N, Becker BN, Hakim RM (1996) Am J Nephrol 16(1): 60-72
    › Primary publication · 8719767 (PubMed)
  118. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF (1996) J Am Soc Nephrol 7(3): 472-8
    › Primary publication · 8704114 (PubMed)
  119. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Sreedhara R, Itagaki I, Hakim RM (1996) Am J Kidney Dis 27(3): 355-64
    › Primary publication · 8604704 (PubMed)
  120. Spontaneous dietary protein intake during progression of chronic renal failure. Ikizler TA, Greene JH, Wingard RL, Parker RA, Hakim RM (1995) J Am Soc Nephrol 6(5): 1386-91
    › Primary publication · 8589313 (PubMed)
  121. Initiation of dialysis. Hakim RM, Lazarus JM (1995) J Am Soc Nephrol 6(5): 1319-28
    › Primary publication · 8589305 (PubMed)
  122. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. Schulman G, Hakim R, Arias R, Silverberg M, Kaplan AP, Arbeit L (1993) J Am Soc Nephrol 3(9): 1563-9
    › Primary publication · 8507811 (PubMed)
  123. The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Schulman G, Wingard RL, Hutchison RL, Lawrence P, Hakim RM (1993) Am J Kidney Dis 21(5): 527-34
    › Primary publication · 8488821 (PubMed)
  124. Use of a novel bioartificial liver in a patient with acute liver insufficiency. Neuzil DF, Rozga J, Moscioni AD, Ro MS, Hakim R, Arnaout WS, Demetriou AA (1993) Surgery 113(3): 340-3
    › Primary publication · 8441969 (PubMed)
  125. Malnutrition in hemodialysis patients. Hakim RM, Levin N (1993) Am J Kidney Dis 21(2): 125-37
    › Primary publication · 8430672 (PubMed)
  126. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Rozga J, Williams F, Ro MS, Neuzil DF, Giorgio TD, Backfisch G, Moscioni AD, Hakim R, Demetriou AA (1993) Hepatology 17(2): 258-65
    › Primary publication · 8428723 (PubMed)
  127. Report of workshop on technique and technology. Hakim RM, Nissenson AR (1993) Am J Kidney Dis 21(1): 109-10
    › Primary publication · 8418613 (PubMed)
  128. Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM (1993) J Am Soc Nephrol 4(2): 178-86
    › Primary publication · 8400081 (PubMed)
  129. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Zaoui P, Hakim RM (1993) Kidney Int 43(6): 1298-305
    › Primary publication · 8315942 (PubMed)
  130. Renal replacement therapies in the elderly: Part II. Renal transplantation. Ismail N, Hakim RM, Helderman JH (1994) Am J Kidney Dis 23(1): 1-15
    › Primary publication · 8285183 (PubMed)
  131. Renal replacement therapies in the elderly: Part 1. Hemodialysis and chronic peritoneal dialysis. Ismail N, Hakim RM, Oreopoulos DG, Patrikarea A (1993) Am J Kidney Dis 22(6): 759-82
    › Primary publication · 8250022 (PubMed)
  132. Clinical implications of hemodialysis membrane biocompatibility. Hakim RM (1993) Kidney Int 44(3): 484-94
    › Primary publication · 8231020 (PubMed)
  133. Effects of dose of dialysis on morbidity and mortality. Hakim RM, Breyer J, Ismail N, Schulman G (1994) Am J Kidney Dis 23(5): 661-9
    › Primary publication · 8172208 (PubMed)
  134. Initiation of dialysis. Hakim RM (1994) Adv Nephrol Necker Hosp : 295-309
    › Primary publication · 8154361 (PubMed)
  135. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM (1994) Kidney Int 45(5): 1477-83
    › Primary publication · 8072261 (PubMed)
  136. Biocompatibility and risk of infection in haemodialysis patients. Himmelfarb J, Hakim RM (1994) Nephrol Dial Transplant : 138-44
    › Primary publication · 8065605 (PubMed)
  137. The effects of the dialysis membrane on cytokine release. Zaoui P, Hakim RM (1994) J Am Soc Nephrol 4(9): 1711-8
    › Primary publication · 8011981 (PubMed)
  138. Amino acid and albumin losses during hemodialysis. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM (1994) Kidney Int 46(3): 830-7
    › Primary publication · 7996804 (PubMed)
  139. Recommendations for reducing the high morbidity and mortality of United States maintenance dialysis patients. The National Kidney Foundation. Kopple JD, Hakim RM, Held PJ, Keane WF, King K, Lazarus JM, Parker TF, Teehan BP (1994) Am J Kidney Dis 24(6): 968-73
    › Primary publication · 7985678 (PubMed)
  140. Effect of the dialysis membrane in the treatment of patients with acute renal failure. Hakim RM, Wingard RL, Parker RA (1994) N Engl J Med 331(20): 1338-42
    › Primary publication · 7935703 (PubMed)
  141. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Wingard RL, Parker RA, Ismail N, Hakim RM (1995) Am J Kidney Dis 25(3): 433-9
    › Primary publication · 7872321 (PubMed)
  142. Short-term effects of recombinant human growth hormone in CAPD patients. Ikizler TA, Wingard RL, Breyer JA, Schulman G, Parker RA, Hakim RM (1994) Kidney Int 46(4): 1178-83
    › Primary publication · 7861714 (PubMed)
  143. Endotoxin transfer during dialysis: less than meets the eye? Hakim RM (1994) J Lab Clin Med 124(6): 742-3
    › Primary publication · 7798782 (PubMed)
  144. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. Becker BN, Fuchs H, Hakim R (1995) J Am Soc Nephrol 5(10): 1746-50
    › Primary publication · 7787141 (PubMed)
  145. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Sreedhara R, Itagaki I, Lynn B, Hakim RM (1995) Am J Kidney Dis 25(4): 555-63
    › Primary publication · 7702050 (PubMed)
  146. Hemodialysis membrane biocompatibility in acute renal failure. Schulman G, Hakim R (1994) Adv Ren Replace Ther 1(1): 75-82
    › Primary publication · 7641091 (PubMed)
  147. Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Ikizler TA, Wingard RL, Hakim RM (1995) Am J Kidney Dis 26(1): 256-65
    › Primary publication · 7611260 (PubMed)
  148. Continuous ambulatory peritoneal dialysis--quo vadis? Teehan BP, Hakim R (1995) J Am Soc Nephrol 6(2): 139-43
    › Primary publication · 7579077 (PubMed)
  149. Malnutrition in peritoneal dialysis patients: etiologic factors and treatment options. Ikizler TA, Wingard RL, Hakim RM (1995) Perit Dial Int 15(5 Suppl): S63-6
    › Primary publication · 7578490 (PubMed)
  150. Panel conference. Blood surface interactions. Lindsay RM, Mason RG, Kim SW, Andrade JD, Hakim RM (1980) Trans Am Soc Artif Intern Organs : 603-10
    › Primary publication · 7245560 (PubMed)
  151. Effect of dialyzer reuse on leukopenia, hypoxemia and total hemolytic complement system. Hakim RM, Lowrie EG (1980) Trans Am Soc Artif Intern Organs : 159-64
    › Primary publication · 7245475 (PubMed)
  152. Cardiovascular instability during hemodialysis. Lazarus JM, Henderson LW, Kjellstrand CM, Weiner MW, Henrich WL, Hakim RM (1982) Trans Am Soc Artif Intern Organs : 656-65
    › Primary publication · 7164319 (PubMed)
  153. Hemodialysis-associated neutropenia and hypoxemia: the effect of dialyzer membrane materials. Hakim RM, Lowrie EG (1982) Nephron 32(1): 32-9
    › Primary publication · 6817150 (PubMed)
  154. The effect on patient health of using reprocessed artificial kidneys. Lowrie EG, Hakim RM (1980) Proc Clin Dial Transplant Forum : 86-91
    › Primary publication · 6810358 (PubMed)
  155. The relative effect of leukopenia and dialysate composition on the dialysis-associated hypoxemia. Hakim RM, Lowrie EG (1980) Proc Clin Dial Transplant Forum : 190-5
    › Primary publication · 6810343 (PubMed)
  156. Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Hakim RM, Goldszer RC, Brenner BM (1984) Kidney Int 25(6): 930-6
    › Primary publication · 6381857 (PubMed)
  157. Biocompatibility of dialysis membranes: effects of chronic complement activation. Hakim RM, Fearon DT, Lazarus JM (1984) Kidney Int 26(2): 194-200
    › Primary publication · 6334194 (PubMed)
  158. Complement activation and hypersensitivity reactions to dialysis membranes. Hakim RM, Breillatt J, Lazarus JM, Port FK (1984) N Engl J Med 311(14): 878-82
    › Primary publication · 6332276 (PubMed)
  159. Increased expression of the C3b receptor by neutrophils and complement activation during haemodialysis. Lee J, Hakim RM, Fearon DT (1984) Clin Exp Immunol 56(1): 205-14
    › Primary publication · 6232024 (PubMed) · PMC1535978 (PubMed Central)
  160. Formaldehyde kinetics and bacteriology in dialyzers. Hakim RM, Friedrich RA, Lowrie EG (1985) Kidney Int 28(6): 936-43
    › Primary publication · 4087700 (PubMed)
  161. Successful management of thrombocytopenia, microangiopathic anemia, and acute renal failure by plasmapheresis. Hakim RM, Schulman G, Churchill WH, Lazarus JM (1985) Am J Kidney Dis 5(3): 170-6
    › Primary publication · 4038847 (PubMed)
  162. Vascular access for hemodialysis. Patency rates and results of revision. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL (1985) Ann Surg 202(2): 235-9
    › Primary publication · 4015229 (PubMed) · PMC1250879 (PubMed Central)
  163. Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. Hakim RM, Pontzer MA, Tilton D, Lazarus JM, Gottlieb MN (1985) Kidney Int 28(3): 535-40
    › Primary publication · 3906227 (PubMed)
  164. Hemodialysis-associated platelet activation and thrombocytopenia. Hakim RM, Schafer AI (1985) Am J Med 78(4): 575-80
    › Primary publication · 3885730 (PubMed)
  165. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR (1985) N Engl J Med 312(8): 457-62
    › Primary publication · 3881672 (PubMed)
  166. Clinical sequelae of complement activation in hemodialysis. Hakim RM (1986) Clin Nephrol : S9-12
    › Primary publication · 3829474 (PubMed)
  167. Iron overload and mobilization in long-term hemodialysis patients. Hakim RM, Stivelman JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, Lazarus JM (1987) Am J Kidney Dis 10(4): 293-9
    › Primary publication · 3661550 (PubMed)
  168. Biochemical parameters in chronic renal failure. Hakim RM, Lazarus JM (1988) Am J Kidney Dis 11(3): 238-47
    › Primary publication · 3125741 (PubMed)
  169. Progression of chronic renal failure. Hakim RM, Lazarus JM (1989) Am J Kidney Dis 14(5): 396-401
    › Primary publication · 2816931 (PubMed)
  170. Reduced angiotensin receptors and pressor responses in hypotensive hemodialysis patients. Moore TJ, Lazarus JM, Hakim RM (1989) Kidney Int 36(4): 696-701
    › Primary publication · 2681934 (PubMed)
  171. Beta-2-microglobulin amyloidosis in long-term dialysis patients. Stone WJ, Hakim RM (1989) Am J Nephrol 9(3): 177-83
    › Primary publication · 2667360 (PubMed)
  172. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM (1989) Kidney Int 36(6): 1125-32
    › Primary publication · 2601259 (PubMed)
  173. Assessing the adequacy of dialysis. Hakim RM (1990) Kidney Int 37(2): 822-32
    › Primary publication · 2407892 (PubMed)
  174. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Lazarus JM, Hakim RM, Newell J (1990) Am J Kidney Dis 16(2): 101-8
    › Primary publication · 2382644 (PubMed)
  175. Effects of dialysis membranes on beta 2-microglobulin production and cellular expression. Zaoui PM, Stone WJ, Hakim RM (1990) Kidney Int 38(5): 962-8
    › Primary publication · 2266681 (PubMed)
  176. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM (1990) Am J Kidney Dis 16(5): 423-31
    › Primary publication · 2239932 (PubMed)
  177. Severe endothelial injury in a renal transplant patient receiving cyclosporine. Fogo A, Hakim RC, Sugiura M, Inagami T, Kon V (1990) Transplantation 49(6): 1190-2
    › Primary publication · 2193445 (PubMed)
  178. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Zaoui P, Green W, Hakim RM (1991) Kidney Int 39(5): 1020-6
    › Primary publication · 2067197 (PubMed)
  179. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Vanholder R, Ringoir S, Dhondt A, Hakim R (1991) Kidney Int 39(2): 320-7
    › Primary publication · 2002645 (PubMed)
  180. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Himmelfarb J, Lazarus JM, Hakim R (1991) Am J Kidney Dis 17(3): 271-6
    › Primary publication · 1996568 (PubMed)
  181. Extracorporeal treatment of familial hypercholesterolemia with monoclonal antibodies to low-density lipoprotein. Wingard RL, Lee WO, Hakim RM (1991) Am J Kidney Dis 18(5): 559-65
    › Primary publication · 1951335 (PubMed)
  182. Recent advances in the biocompatibility of haemodialysis membranes. Schulman G, Hakim RM (1991) Nephrol Dial Transplant : 10-3
    › Primary publication · 1866056 (PubMed)
  183. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW (1991) J Am Soc Nephrol 2(6): 1130-5
    › Primary publication · 1777593 (PubMed)
  184. Complement activation retards resolution of acute ischemic renal failure in the rat. Schulman G, Fogo A, Gung A, Badr K, Hakim R (1991) Kidney Int 40(6): 1069-74
    › Primary publication · 1762308 (PubMed)
  185. Intradialytic modulation of granulocyte C5a receptors. Himmelfarb J, Gerard NP, Hakim RM (1991) J Am Soc Nephrol 2(4): 920-6
    › Primary publication · 1751793 (PubMed)
  186. Adequacy of hemodialysis. Hakim RM, Depner TA, Parker TF (1992) Am J Kidney Dis 20(2): 107-23
    › Primary publication · 1496963 (PubMed)
  187. NKF lends direction to defining the patient-care technician role. Parker TF, Kammerer J, Hover J, Hakim R, Levin NW, Messana A, Burrows-Hudson S (1992) Nephrol News Issues 6(4): 54
    › Primary publication · 1407040 (PubMed)
  188. The dose of hemodialysis according to dialysis prescription in Europe and the United States. Held PJ, Blagg CR, Liska DW, Port FK, Hakim R, Levin N (1992) Kidney Int Suppl : S16-21
    › Primary publication · 1405368 (PubMed)
  189. Modulation of granulocyte LAM-1 and MAC-1 during dialysis--a prospective, randomized controlled trial. Himmelfarb J, Zaoui P, Hakim R (1992) Kidney Int 41(2): 388-95
    › Primary publication · 1372668 (PubMed)
  190. Detection of granulocyte reactive oxygen species formation in whole blood using flow cytometry. Himmelfarb J, Hakim RM, Holbrook DG, Leeber DA, Ault KA (1992) Cytometry 13(1): 83-9
    › Primary publication · 1372205 (PubMed)
  191. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R (1979) Can Med Assoc J 121(5): 591-4
    › Primary publication · 497950 (PubMed) · PMC1704442 (PubMed Central)